These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 34314880)

  • 1. Next-Generation Sequencing Concordance Analysis of Comprehensive Solid Tumor Profiling between a Centralized Specialty Laboratory and the Decentralized Personal Genome Diagnostics elio Tissue Complete Kitted Solution.
    Deak KL; Jackson JB; Valkenburg KC; Keefer LA; Robinson Gerding KM; Angiuoli SV; Datto MB; McCall SJ
    J Mol Diagn; 2021 Oct; 23(10):1324-1333. PubMed ID: 34314880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Automated next-generation profiling of genomic alterations in human cancers.
    Keefer LA; White JR; Wood DE; Gerding KMR; Valkenburg KC; Riley D; Gault C; Papp E; Vollmer CM; Greer A; Hernandez J; McGregor PM; Zingone A; Ryan BM; Deak K; McCall SJ; Datto MB; Prescott JL; Thompson JF; Cerqueira GC; Jones S; Simmons JK; McElhinny A; Dickey J; Angiuoli SV; Diaz LA; Velculescu VE; Sausen M
    Nat Commun; 2022 May; 13(1):2830. PubMed ID: 35595835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Validation of StrataNGS, a Multiplex PCR, Semiconductor Sequencing-Based Comprehensive Genomic Profiling Test.
    Tomlins SA; Hovelson DH; Harms P; Drewery S; Falkner J; Fischer A; Hipp J; Kwiatkowski K; Lazo de la Vega L; Mitchell K; Reeder T; Siddiqui J; Vakil H; Johnson DB; Rhodes DR
    J Mol Diagn; 2021 Nov; 23(11):1515-1533. PubMed ID: 34454112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors.
    Milbury CA; Creeden J; Yip WK; Smith DL; Pattani V; Maxwell K; Sawchyn B; Gjoerup O; Meng W; Skoletsky J; Concepcion AD; Tang Y; Bai X; Dewal N; Ma P; Bailey ST; Thornton J; Pavlick DC; Frampton GM; Lieber D; White J; Burns C; Vietz C
    PLoS One; 2022; 17(3):e0264138. PubMed ID: 35294956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing.
    Al Zoughbi W; Fox J; Beg S; Papp E; Hissong E; Ohara K; Keefer L; Sigouros M; Kane T; Bockelman D; Nichol D; Patchell E; Bareja R; Karandikar A; Alnajar H; Cerqueira G; Guthrie VB; Verner E; Manohar J; Greco N; Wilkes D; Tagawa S; Malbari MS; Holcomb K; Eng KW; Shah M; Altorki NK; Sboner A; Nanus D; Faltas B; Sternberg CN; Simmons J; Houvras Y; Molina AM; Angiuoli S; Elemento O; Mosquera JM
    Oncologist; 2021 Nov; 26(11):e1971-e1981. PubMed ID: 34286887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the Oncomine
    Williams HL; Walsh K; Diamond A; Oniscu A; Deans ZC
    Virchows Arch; 2018 Oct; 473(4):489-503. PubMed ID: 30105577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy.
    Gray PN; Vuong H; Tsai P; Lu HM; Mu W; Hsuan V; Hoo J; Shah S; Uyeda L; Fox S; Patel H; Janicek M; Brown S; Dobrea L; Wagman L; Plimack E; Mehra R; Golemis EA; Bilusic M; Zibelman M; Elliott A
    Oncotarget; 2016 Oct; 7(42):68206-68228. PubMed ID: 27626691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors.
    Conroy JM; Pabla S; Glenn ST; Seager RJ; Van Roey E; Gao S; Burgher B; Andreas J; Giamo V; Mallon M; Lee YH; DePietro P; Nesline M; Wang Y; Lenzo FL; Klein R; Zhang S
    PLoS One; 2021; 16(12):e0260089. PubMed ID: 34855780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
    Pécuchet N; Legras A; Laurent-Puig P; Blons H
    Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort.
    Bevins N; Sun S; Gaieb Z; Thorson JA; Murray SS
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variant call concordance between two laboratory-developed, solid tumor targeted genomic profiling assays using distinct workflows and sequencing instruments.
    Hampel KJ; de Abreu FB; Sidiropoulos N; Peterson JD; Tsongalis GJ
    Exp Mol Pathol; 2017 Apr; 102(2):215-218. PubMed ID: 28192086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients.
    Lee SH; Lee B; Shim JH; Lee KW; Yun JW; Kim SY; Kim TY; Kim YH; Ko YH; Chung HC; Yu CS; Lee J; Rha SY; Kim TW; Jung KH; Im SA; Moon HG; Cho S; Kang JH; Kim J; Kim SK; Ryu HS; Ha SY; Kim JI; Chung YJ; Kim C; Kim HL; Park WY; Noh DY; Park K
    Cancer Res Treat; 2019 Jan; 51(1):211-222. PubMed ID: 29690749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of a Molecular Diagnostic Test for Circulating Tumor DNA by Next-Gen Sequencing.
    Fernandez SV; Tan YF; Rao S; Fittipaldi P; Sheriff F; Borghaei H; Dotan E; Winn JS; Edelman MJ; Treat J; Judd J; Alpaugh RK; Wang YL; Yu JQ; Wasik M; Baldwin DA
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct next-generation sequencing analysis using endometrial liquid-based cytology specimens for rapid cancer genomic profiling.
    Akahane T; Kitazono I; Kobayashi Y; Nishida-Kirita Y; Yamaguchi T; Yanazume S; Tabata K; Kobayashi H; Tanimoto A
    Diagn Cytopathol; 2021 Sep; 49(9):1078-1085. PubMed ID: 34319014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Creation of an Expert Curated Variant List for Clinical Genomic Test Development and Validation: A ClinGen and GeT-RM Collaborative Project.
    Wilcox E; Harrison SM; Lockhart E; Voelkerding K; Lubin IM; ; Rehm HL; Kalman LV; Funke B
    J Mol Diagn; 2021 Nov; 23(11):1500-1505. PubMed ID: 34384894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies.
    Cao J; Chen L; Li H; Chen H; Yao J; Mu S; Liu W; Zhang P; Cheng Y; Liu B; Hu Z; Chen D; Kang H; Hu J; Wang A; Wang W; Yao M; Chrin G; Wang X; Zhao W; Li L; Xu L; Guo W; Jia J; Chen J; Wang K; Li G; Shi W
    Oncologist; 2019 Dec; 24(12):e1294-e1302. PubMed ID: 31409745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Homologous Recombination Repair Gene Next-Generation Sequencing Analysis in Patients With Metastatic Castration-Resistant Prostate Cancer Between Local and Central Laboratories in Korea.
    Kim Y; Park I; Kim B; Choi YJ; Oh SC; Lee KA
    Ann Lab Med; 2023 Jan; 43(1):64-72. PubMed ID: 36045058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors.
    Takeda M; Takahama T; Sakai K; Shimizu S; Watanabe S; Kawakami H; Tanaka K; Sato C; Hayashi H; Nonagase Y; Yonesaka K; Takegawa N; Okuno T; Yoshida T; Fumita S; Suzuki S; Haratani K; Saigoh K; Ito A; Mitsudomi T; Handa H; Fukuoka K; Nakagawa K; Nishio K
    Oncologist; 2021 Apr; 26(4):e588-e596. PubMed ID: 33325566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a Hybrid Capture-Based Pan-Cancer Panel for Analysis of Treatment Stratifying Oncogenic Aberrations and Processes.
    Kroeze LI; de Voer RM; Kamping EJ; von Rhein D; Jansen EAM; Hermsen MJW; Barberis MCP; Botling J; Garrido-Martin EM; Haller F; Lacroix L; Maes B; Merkelbach-Bruse S; Pestinger V; Pfarr N; Stenzinger A; van den Heuvel MM; Grünberg K; Ligtenberg MJL
    J Mol Diagn; 2020 Jun; 22(6):757-769. PubMed ID: 32205293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.